Figure 2 Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Slides:

Advertisements

Similar presentations

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy by Emanuela Zappia, Simona Casazza, Enrico Pedemonte,

Advertisements

Figure 3 Test reliability of enzymatic dissociation methods

Figure 5 Mononuclear cell subset isolation from spinal cord of mice with experimental autoimmune encephalomeylitis Mononuclear cell subset isolation from.

Figure 1 Percent positivity by clinical feature Overall, 6

Figure 2 Anti-LINGO-1 (Li81) does not affect cytokine production

Volume 32, Issue 3, Pages (March 2010)

Figure 3 Immune response to neoantigen: Geometric mean titers of antirabies antibody levels over timeAt days 31 and 38, all subjects achieved antibody.

Volume 42, Issue 4, Pages (April 2015)

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Figure 2 APCs from laquinimod-treated mice inhibit differentiation of Tfh cells APCs from laquinimod-treated mice inhibit differentiation of Tfh cells.

Figure 6 Laquinimod treatment of spontaneous EAE prevents progression and reduces the frequency of Tfh cells Laquinimod treatment of spontaneous EAE prevents.

Cardiac dysfunction induced by experimental myocardial infarction impairs the host defense response to bacterial infection in mice because of reduced.

Figure 2 Mean serum concentrations of BIIB033 vs time(A) Single ascending dose study and (B) multiple ascending dose study. Mean serum concentrations of.

Figure 4 Glatiramer acetate treatment negatively regulates IFN-β production by targeting components of the IFN-β enhanceosome (A) Wild-type (WT) monocytes.

Figure 3 Responder subset (A) Percentage of “responders” (nonprogressing patients) at week 25 after 6 months of treatment; percentage of “responders” in.

Volume 86, Issue 4, Pages (October 2014)

Figure 2 Mononuclear cell numbers after enzymatic dissociation methods in mice with clinical experimental autoimmune encephalomyelitis Mononuclear cell.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Evolution of blood cell counts during 18-month treatment and follow-up (A) Mean white blood cell count, (B) mean lymphocyte count, (C) mean eosinophil.

Figure 4 Pattern of relapse in patients with MOG-Ab Five myelin oligodendrocyte glycoprotein antibody (MOG-Ab)–positive patients experienced a relapse,

Volume 36, Issue 6, Pages (June 2012)

Volume 33, Issue 4, Pages (October 2010)

Volume 18, Issue 4, Pages (April 2010)

Figure 2 Individual EDSS scores

Figure 4 Laquinimod treatment suppresses development of spontaneous EAE Laquinimod treatment suppresses development of spontaneous EAE (A) 2D2 × Th mice.

Volume 43, Issue 6, Pages (December 2015)

Volume 35, Issue 2, Pages (August 2011)

Figure 1 Annual trend in specimen type submitted as first sample for aquaporin-4 immunoglobulin G testing (serum only vs CSF only vs both) from 101,065.

Figure 5 ADP-induced inflammatory responses require P2Y12 receptors in human microgliaIncreasing concentrations of ADP (5, 50, and 200 μM) increased tumor.

Figure 2 Distinct changes to immunoprofile in autoimmune thyroid disease (AITD) and multiple sclerosis (MS)‏ Distinct changes to immunoprofile in autoimmune.

Figure 6 Cellular composition after tissue dissociation

Figure 3 Cytokine gene expression in PBMC stimulated with PPD or MBP in vitroCytokine messenger RNA transcripts were isolated from peripheral blood mononuclear.

Volume 34, Issue 3, Pages (March 2011)

Figure 1 Association between serum levels of IL-18 and hippocampal volume in patients with schizophrenia Scatter plots show a positive correlation between.

Figure 1 Laquinimod treatment reduces the frequency of Tfh cells and IL-21–producing T cells in rMOG-induced EAE Laquinimod treatment reduces the frequency.

Figure 2 Induced deletion of CXCR2 on oligodendrocyte lineage cells after tamoxifen injection in Cxcr2-cKO mice Induced deletion of CXCR2 on oligodendrocyte.

Figure 4 Alemtuzumab-mediated effects on interleukin (IL)–23 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in innate myeloid.

Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on cytokines and experimental autoimmune encephalomyelitis.

Volume 14, Issue 3, Pages (March 2001)

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Figure 2. Odds ratios (ORs) from the multivariate logistic regression analysis and hazard ratios (HRs) from the Cox regression analysis Odds ratios (ORs)

Figure 2 Correlation between wGRS and age at onset The figure shows the correlation between weighted genetic risk score (wGRS) and age at onset in all.

Figure 4 Prevention of onset of behavioral deficits following 3-month treatment of Baxter IG in Dutch APP E693Q transgenic mice Prevention of onset of.

Figure 2 Assessment of systemic disease activityTc99 scintigraphy (A) and fluorodeoxyglucose PET imaging (B, C) at disease onset 2 years before acute deterioration.

Figure 4 Increased susceptibility of MIF−/− CD4+ T cells to immunosuppression by Dex in EAE (A) MOG35-55 peptide-activated donor cells from wild-type (Wt)

Figure 4. The N:M ratio is significantly increased in patients with ALS and correlates with disease progression The N:M ratio is significantly increased.

Figure 1 Full-length MOG cell-based assay using a serum dilution of 1:160 as a cutoff for positivity (red line in both plots)(A) Myelin olidgodendrocyte.

Figure Avidity of IgG specific for influenza A and B following flu vaccinationAvidity of immunoglobulin (Ig) G specific for influenza A and B before and.

Figure 2 Glatiramer acetate treatment induced M2 differentiation through a MyD88-independent pathway (A) As described previously,3 M2 monocytes were treated.

Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.

IFN-γ–producing cells in the spleen and lungs postimmunization.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Figure 3 Impact of short-term MP administration on frequency and phenotype of slanDCs and monocytes in the blood of patients with MSThe percentages of.

Figure 1. MBP-specific IFN-γ+ but not IL-17+ frequencies are significantly different between patients with MS and HCs MBP-specific IFN-γ+ but not IL-17+

Figure 3 Downregulation of T-bet expression in brain-infiltrating MIF−/− CD4+ T cells Macrophage migration inhibitory factor (MIF)−/− and wild-type (Wt)

Figure 2 B-cell very late antigen-4 (VLA-4) deficiency reduced CNS accumulation of B cells, but not proinflammatory or regulatory T cells (Treg), in myelin.

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Figure 3 Fingolimod inhibits TNF-α secretion by human monocytes Peripheral blood mononuclear cells from healthy donors were briefly exposed to increasing.

Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau

Gitanjali Das et al. Neurol Neuroimmunol Neuroinflamm 2018;5:e453

Figure 1 EAE severity and CNS pathology in Dex-treated MIF−/− and Wt mice Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Volume 20, Issue 7, Pages (July 2012)

Figure 1 Tissue processing methods and cellular viability

Figure 4 Cell count of selective immune cell subpopulations during alemtuzumab Cell count of selective immune cell subpopulations during alemtuzumab Absolute.

Figure 2 Interleukin-6 concentrations in the CSF In 2 mutation carriers (patient 1 in dark blue triangle and patient 5 in light blue triangle carrying.

Figure 2. Percentage of CD16− monocytes in the blood is reduced during disease progression Percentage of CD16− monocytes in the blood is reduced during.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

Figure 4 Longitudinal analysis of peripheral immune cell composition Frequency of naive, central memory (Tcm), and effector memory (Tem) CD4 T cells over.

Presentation transcript:

Figure 2 Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were immunized to induce experimental autoimmune encephalomyelitis (EAE) and injected intraperitoneally with 10 mg/kg dexamethasone (Dex) vs phosphate-buffered saline (PBS) control for 3 continuous days upon onset of disease, as shown in figure 1B. Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were immunized to induce experimental autoimmune encephalomyelitis (EAE) and injected intraperitoneally with 10 mg/kg dexamethasone (Dex) vs phosphate-buffered saline (PBS) control for 3 continuous days upon onset of disease, as shown in figure 1B. Spleens (A, B) and brain mononuclear cells (MNCs) (C, D) of EAE mice were harvested at different time points and restimulated with MOG35-55 peptide. The frequencies of Th1 and Th17 cytokine-producing T cells were measured by ELISPOT assay as described in the Methods. Shown are pooled data from 2 to 4 independent experiments (mean ± SEM; onset, n = 7–14 mice per group from day 10 postimmunization and after 3 injections of Dex or PBS; acute, n = 5 mice per group from day 16–24 postimmunization when PBS groups reached peak score of 2 or higher; chronic, n = 6–8 mice per group from day 26–36, usually 10 days after PBS groups remitted from peak of disease; analysis of variance; *p < 0.05; **p < 0.01). IFN = interferon; IL = interleukin; NS = not significant; SFC = spot-forming cells. Niannian Ji et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e139 © 2015 American Academy of Neurology